Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Shire PLC (SHP): Should You Buy In?

LONDON — Shares in pharmaceuticals play Shire PLC (LON:SHP) have endured a turbulent start to 2013, collapsing 8.8% from February’s near-one-year high around 2,150 pence after takeover speculation had earlier propelled stocks higher.

Shire PLC (LON:SHP)Despite this recent weakness, I believe that stock in the pharmaceuticals giant should head skywards again as galloping R&D work, combined with the likelihood of busy acquisition activity, drives growth in coming years. Goldman Sachs affirmed its 2,675 pence share price target just this month, representing 36% upside from current levels.

Stunning growth potential to drive sales
I believe that the firm’s prolific research and development activity should deliver solid revenue growth over the long term. Shire PLC (LON:SHP) spent $848.8 million on this area last year, a 16% annual rise, which should boost its pipeline and deliver excellent sales further out. Indeed, Goldman Sachs expects revenues to grow around 10% through to 2017 versus a 3% rise across the entire pharma sector.

And Shire PLC (LON:SHP)’s sterling record of innovation should be underpinned by M&A activity in coming years as it puts its $1.4 billion cash pile to work. Shire PLC (LON:SHP) acquired SARCode Bioscience just last month to boost its opthalmology business — the U.S. firm’s phase 3 compound Lifitegrast product is being tested for dry eye disease. The move follows the purchase of Sweden’s Premacure AB in February, which is currently in phase 2 testing for the prevention of eye disorder retinopathy of prematurity, or ROP.

Earnings explosion predicted for 2013
City forecasters expect earnings per share to snap 68% higher in 2013, following last year’s 14% decline, with a rise to 147 pence penciled in. These are then expected to advance 14% in 2014 to 168 pence.

The company currently changes hands on a P/E rating of 13.5 and 11.9 for 2013 and 2014, respectively, providing a bloated discount to a forward earnings multiple of 39.7 for the broad pharmaceuticals and biotechnology sector. And Shire PLC (LON:SHP)’s position as a true value stock is underlined by a low price/earnings to growth, or PEG, rating of 0.2 and 0.8 for this year and next — a reading below 1 is considered excellent value for money.

Despite Shire PLC (LON:SHP)’s recent buyback program — the firm commenced a $500 million purchase scheme late last year — the stock does not provide an attractive pick for income investors, with dividend yields of just 0.6% and 0.7% predicted for this year and next below the wider sector’s average 2.4% payout.

However, in my opinion Shire PLC (LON:SHP)’s decision to allocate its meaty cash pile toward developing future growth makes it an exciting pick, with revenues ready to balloon in coming years.

The canny guide for clever investors
If you already hold shares in Shire, check out this newly updated special report that highlights a host of other FTSE winners identified by ace fund manager Neil Woodford.

Woodford — head of UK Equities at Invesco Perpetual — has more than 30 years’ experience in the industry, and has identified three other fantastic pharmaceutical firms in the report set to deliver spectacular investor returns.

The article Should You Buy Shire Today? originally appeared on

Fool contributor Royston Wild and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.